Clinically approved HIF-PHIs modulate redox metabolism, cell growth, and angiogenesis independent of HIF-1α/HIF-2α

HIF-prolyl hydroxylase inhibitors are used to treat anemia in chronic kidney disease. These drugs stabilize hypoxia-inducible factors HIF-1α and HIF-2α, which activate erythropoiesis and iron metabolism pathways. Clinically approved HIF-PHIs including roxadustat and molidustat exhibit distinct molec...

Descrición completa

Detalles Bibliográficos

Principais autores:	Daniela Mennerich, Fawzi Khoder-Agha, Mustafa Beter, Elitsa Y. Dimova, Seppo Ylä-Herttuala, Thomas Kietzmann
Formato:	Artigo
Idioma:	Inglês
Publicado:	Elsevier 2026-07-01
Series:	Redox Biology
Assuntos:	HIF-1α HIF-2α Roxadustat Molidustat RNAseq
Acceso en liña:	http://www.sciencedirect.com/science/article/pii/S2213231726002041
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!